Asia sees healthy gains in Biden’s presidency

GlobeNewswire

CareDx announces price of public offering of common shares

SOUTH SAN FRANCISCO, Calif., January 20, 2021 (GLOBE NEWSWIRE) – CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically-based healthcare solutions differentiated and of high value to transplant patients and caregivers, today announced the price of a subscribed public offering of 1,923,077 common shares at a public offering price of $ 91.00 per action. The gross proceeds of this offering for CareDx, before the deduction of underwriting discounts and offering commissions and fees, are expected to be $ 175,000,007. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 288,461 additional shares of its common shares offered under the public offering on the same terms. The offer is expected to close around January 25, 2021, subject to the satisfaction of customary closing conditions. CareDx intends to use the net proceeds of this offering for working capital and general business purposes. Goldman Sachs & Co. LLC and Jefferies LLC are acting as co-bookkeepers for the offering. Raymond James & Associates, Inc .; BTIG, LLC; Craig-Hallum Capital Group LLC and HC Wainwright & Co., LLC are acting as co-managers of the offering. The public offering will be made in accordance with a prior registration statement on Form S-3ASR (File No. 333-239049) previously filed with the Securities and Exchange Commission (the “SEC”) on June 9, 2020, which entered Effective immediately the filing in accordance with SEC rules. The securities can only be offered by prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offer have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus and, where available, copies of the final prospectus supplement and accompanying prospectus relating to the offering can be obtained from Goldman Sachs & Co. LLC, Attn .: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected] or by phone at (866) 471-2526; or Jefferies LLC, Attn .: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at [email protected] or by phone at (877) 821-7388. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. before registration or qualification. under the securities laws of those states or jurisdictions. About CareDxCareDx, Inc., headquartered in Southern San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of healthcare solutions clinically differentiated and of great value to transplant patients and caregivers. CareDx provides digital health products, testing services and solutions throughout the patient’s journey before and after transplantation, and is the leading provider of genomics-based information for transplant patients. Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the public offering subscribed and the expected closing date thereof as well as the amount and use of the expected product offers. These forward-looking statements are based on information currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with market conditions and satisfaction. customary closing conditions. related to the proposed public offering, as well as general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the annual report on Form 10-K for the year ended December 31 2019 filed by CareDx with the SEC on February 28, 2020 and the periodic reports that CareDx has subsequently filed with the SEC, and the preliminary prospectus supplement relating to the proposed offering filed with the SEC as of the date hereof or around that date. Each of these elements may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertakes to update or revise these forward-looking statements. CONTACTS: Investor relationsGreg [email protected]